Entera Bio (ENTX) Current Assets (2017 - 2026)

Entera Bio has disclosed Current Assets across 9 years of filings, most recently posting $12.5 million for Q1 2026.

• Quarterly Current Assets fell 41.12% year-over-year to $12.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.5 million (down 41.12% YoY) and the FY2025 annual result came in at $15.3 million, up 70.51% from the prior year.
• Current Assets declined to $12.5 million in Q1 2026, from $15.3 million in the prior quarter.
• Over five years, Current Assets peaked at $21.6 million in Q1 2022 and troughed at $7.3 million in Q3 2024.
• A 5-year average of $13.5 million and a median of $12.5 million in 2026 frame the typical range for Current Assets.
• Annual changes were most pronounced in 2022 — Current Assets slumped 49.27% — and 2025, when it soared 131.7%.
• Tracing ENTX's Current Assets over 5 years: stood at $12.8 million in 2022, then slipped by 12.39% to $11.3 million in 2023, then declined by 20.3% to $9.0 million in 2024, then soared by 70.51% to $15.3 million in 2025, then fell by 18.34% to $12.5 million in 2026.
• Business Quant data shows ENTX's Current Assets at $12.5 million in Q1 2026, $15.3 million in Q4 2025, and $17.0 million in Q3 2025.